Authors
Latest:
Dr. Arend Discusses Targets in Endometrial CancerRebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.
Latest:
The Future Management of Cervical Cancer: Novel Agents and Clinical Pearls for Community OnclogistsRounding out her discussion on the use of tisotumab vedotin in cervical cancer, Rebecca Arend, MD, MPH, considers other agents being investigated and how that may impact the future treatment landscape.
Latest:
Dr. Dent on Final LOTUS Findings in TNBCRebecca Dent, MD, discusses the findings from the phase 2 LOTUS trial that treated patients with inoperable locally advanced/metastatic triple-negative breast cancer with first-line ipatasertib plus paclitaxel.
Latest:
Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast CancerRebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.
Latest:
Dr Kristeleit on the Implications of Long-Term Data With Rucaparib in Advanced Ovarian CancerRebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.
Latest:
Dr. Aft on Bisphosphonates for Breast CancerRebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.
Latest:
Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AMLRebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.
Latest:
Prevention Program Targets Pancreatic Cancer Before It Gains a FootholdPancreatic cancer is currently the fourth-leading cause of cancer death in the United States, with a 5-year survival rate of approximately 8%.
Latest:
Dr. Sippel Explains Thyroid Cancer Risk FactorsRebecca S. Sippel, MD, from University of Wisconsin, explains the need for added screening for those at high-risk of developing thyroid cancer.
Latest:
The EAR Party's EndElectronic Health Record (EHR) systems hold great promise. However, like many new technologies, the difficulty of achieving EHRs' promise has been vastly underestimated, as have the risks. The current national initiatives pushing for widespread EHR implementation may be leading us into an unmapped minefield.
Latest:
Dr. Friend on the Importance of Work-up for Patients With Multiple MyelomaReed Friend, MD, a medical oncologist in hematology and medical oncology, of Levine Cancer Institute and Carolinas HealthCare System, discusses the importance of appropriate work-ups for patients with multiple myeloma.
Latest:
Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCLReem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCLReem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.
Latest:
Dr. Hegazi on Nutrition-Related Toxicities in OncologyRefaat Hegazi, MD, PhD, MPH, discusses nutrition-related toxicities in oncology.
Latest:
What Is Malware and Why Should I Worry About It?What should you know about malware, what can you do to protect your computer, and what should you do if your computer becomes infected?
Latest:
Dr. Dummer on COMBI-AD Trial Results in BRAF-Mutant MelanomaReinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.
Latest:
Potential Challenges in the Future Treatment of Mantle Cell LymphomaRekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the challenges that exist in the future of treatment for patients with mantle cell lymphoma (MCL).
Latest:
Dr Callahan on Commonly Used Imaging Modalities in Breast CancerRena D. Callahan, MD, discusses the range of metastatic imaging techniques available in breast cancer, the benefits of liquid biopsy, and the importance of looking for bone metastases in patients with metastatic breast cancer.
Latest:
Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTCRenato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).
Latest:
Dr. Martins on Patient Selection for Nivolumab in NSCLCRenato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).
Latest:
Congresswoman Renee Ellmers Discusses the Cancer Patient Protection Act of 2013Congresswoman Renee Ellmers (R-NC-02), U.S. House of Representatives, discusses the importance of the Cancer Patient Protection Act of 2013 (H.R. 1416).
Latest:
Dr. Brentjens Discusses the Goal of Armored CAR T CellsRenier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Dr. Iyer on Treatment of Patients With Lung NETsRenuka Iyer, MD, associate professor of Oncology, co-director, Liver and Pancreas Tumor Center, section chief for Gastrointestinal Oncology, Roswell Park Cancer Institute, assistant professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, discusses treatment of patients with lung neuroendocrine tumors.
